Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC
Roy S. Herbst, Hendrik Tobias Arkenau, Johanna C. Bendell, Edward Arrowsmith, Martin Wermke, A. Segado Soriano, Nicolas Penel, Rafael Santana-Dávila, Helge Bischoff, Ian Chau, Gu Mi, Hong Wang, Erik Rasmussen, David Ferry, Bo H. Chao, Luis Paz‐Ares
Topics & Concepts
MedicinePembrolizumabRamucirumabInternal medicineCohortPopulationAdverse effectBiomarkerOncologyGastroenterologyCancerImmunotherapyBiochemistryEnvironmental healthChemistryCancer Immunotherapy and BiomarkersColorectal and Anal CarcinomasEsophageal Cancer Research and Treatment